Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm study of FXS6837 in PNH patients with persistent anemia despite stable C5 inhibitor therapy
CTR20263909Phase 3Active
- Sponsor
- Xinghao Pengbo
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of FXS6837 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Xinghao Pengbo. Started Oct 2026; status: active.
02
Drugs
FXS6837
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20263909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263909.